Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis.
Rieke E AltenColin MarklandMalcolm BoyceKazuki KawakamiRafael MunizMark C GenovesePublished in: International journal of rheumatic diseases (2020)
The RP and F showed comparable immunogenicity characteristics after long-term administration. Development of ADAs with the RP and F was similar, and was not impacted by switching and double switching between F and RP treatment.
Keyphrases